Παρασκευή 14 Δεκεμβρίου 2018
Steroid-induced perilymphatic hypopigmentation: Response to tacrolimus p. 114 Sneha Ghunawat, Rashmi Sarkar DOI:10.4103/Pigmentinternational.Pigmentinternational_11_18 Intralesional steroids are commonly used in dermatological practice. This route of administration has the advantage of minimal side effects. However, other adverse reactions namely local atrophy, ulceration, infections, etc. have been noted. One peculiar side effect following this route of administration “steroid-induced perilymphatic hypopigmentation and atrophy” has been described below. Although this condition repigments spontaneously, the use of tacrolimus to fasten the response has been highlighted in the case report.
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cincinnati.com No fooling; go get your head (and neck) examined for free Cincinnati.com Thursday, get your head examined. UC Health ...
-
In our previous work, the dichloromethane-methanol (1:1 v/v) extract, fractions and isolated compounds from Polyscias fulva stem bark showed...
-
Nursing students' perceptions of a video-based serious game's educational value: A pilot study. Nurse Educ Today. 2017 Dec 28;...
-
Anaphora is a rhetorical term for the repetition of a word or phrase at the beginning of successive clauses or verses. from #AlexandrosSfa...
-
Abstract We introduce a novel diagnostic Visual Voiding Device (VVD), which has the ability to visually document urinary voiding events an...
-
Abstract Recent updating of the World Health Organization (WHO) classification of central nervous system (CNS) tumors in 2016 demonstrates...
-
Background Agricultural work can expose workers to increased risk of heat strain and volume depletion due to repeated exposures to high ambi...
-
A Tailored Intervention for PAP Adherence: The SCIP-PA Trial. Behav Sleep Med. 2017 Jan 27;:1-25 Authors: Sawyer AM, King TS, Weaver ...
-
Impact of Mandibular Advancement Therapy on Endothelial Function in Severe Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2017 Ja...

Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου